- Home
- S vs WGS Comparison
S vs WGS Comparison
Compare S & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | S | WGS |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.6B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | S | WGS |
|---|---|---|
| Price | $13.14 | $73.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 31 | 7 |
| Target Price | $21.55 | ★ $140.71 |
| AVG Volume (30 Days) | ★ 7.7M | 728.3K |
| Earning Date | 03-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $821,461,000.00 | N/A |
| Revenue This Year | $24.53 | $26.97 |
| Revenue Next Year | $20.04 | $21.78 |
| P/E Ratio | ★ N/A | $1,251.58 |
| Revenue Growth | ★ 32.25 | N/A |
| 52 Week Low | $12.24 | $55.17 |
| 52 Week High | $21.40 | $170.87 |
Technical Indicators
Market Signals| Indicator | S | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 30.16 |
| Support Level | $12.33 | $61.55 |
| Resistance Level | $15.49 | $76.21 |
| Average True Range (ATR) | 0.64 | 5.26 |
| MACD | 0.04 | -0.08 |
| Stochastic Oscillator | 49.86 | 0.72 |
Price Performance
Historical ComparisonAbout S SentinelOne Inc.
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.